Exploratory Study of a Digital Therapeutics in People With Schizophrenia

Inclusion Criteria: * 1\. Is willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments. * 2\. Between 18 and 64 years of age at time of informed consent. * 3\. Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form. * 4\. Has a primary diagnosis of schizophrenia using the diagnostic criteria for schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), for at least 1-year prior to screening. * 5\. Is in the stable phase of illness, as assessed by the investigator after review of medical records or documented discussion with the treating physician. * 6\. Has outpatient treatment status at the time of screening, with no inpatient treatment for schizophrenia within 12 weeks prior to screening. * 7\. Is on a stable dose of antipsychotic medication(s) for at least 12 weeks prior to enrollment (Day 1) as determined by the investigator. * 8\. Has obtained a score of 30 or less on the MAP-SR as assessed at the screening visit. * 9\. Is the sole user, per participant self-report, of an iPhone with an iPhone operating system (iOS) 13 or greater or a smartphone with an Android operating system 9 or greater and is willing to download and use the Study App as required per the protocol. * 10\. Is the owner of, and has regular access to, an email address. * 11\. Has regular access to the internet via cellular data plan and/or wifi. * 12\. Has stable housing and has remained at the same residence for at least 12 weeks prior to screening, with no anticipated housing changes during the duration of the study. * 13\. Understands how to use the Study App during the screening visit as assessed by the investigator during in-clinic Study App installation and activation activities. Exclusion Criteria: * 1\. Is currently treated with more than two antipsychotic medications (including more than two dosage forms). * 2\. Is currently treated with clozapine or haloperidol. * 3\. Has active prominent positive symptoms in the opinion of the investigator that would preclude effective engagement in treatment for negative symptoms. * 4\. Is currently receiving or has received psychotherapy within 12 weeks prior to screening. * 5\. Meets either the International Classification of Diseases, Tenth Revision (ICD-10) or DSM-5 criteria for diagnoses not under investigation, including schizophreniform, schizoaffective, or psychosis non-specific disorders. * 6\. Has post-traumatic stress disorder (PTSD), bipolar disorder, major depressive disorder, developmental disorders, or any prominent disorder that would interfere with compliance to the protocol, per investigator judgment. * 7\. Has substance or alcohol use disorder (excluding caffeine and nicotine), that would interfere with compliance to the protocol, per investigator judgment. * 8\. Currently needs or will likely require prohibited concomitant medications and/or therapy during the study, as determined by the investigator. * 9\. Is currently participating in another clinical study (interventional or observational) involving investigational drugs or devices. * 10\. Prior participation in the CT-155-C-001 clinical study. * 11\. Has suicidal ideation or behavior, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS): 1. Participants with a "yes" response to either Items 4 or 5 on the C-SSRS Suicidal Ideation Item within the last 12 weeks prior to screening or at baseline visit. 2. Participants with a "yes" response on the C-SSRS Suicidal Behavior Items within the last 26 weeks prior to screening or at baseline visit. 3. Participants who, in the opinion of the investigator, present a serious risk of suicide. * 12\. In the judgment of the investigator, any evidence of a clinically significant concomitant disease or any other clinical condition that would jeopardize the participant's safety while participating in the clinical study.